Award NoticePosted Jul 8, 2026

Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products

National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIAID

Stage
Awarded
NAICS
325412
Value
$49.9M
Solicitation
75N95025R00005
Set-aside
No Set aside used
PSC
AN12
Place
Menlo Park, CA, USA
Contact
Patrick Finn (patrick.finn@nih.gov)

No listed company matched (Materiality N/A)

Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 75N95025R00005 in this department, oldest first.

Early notice
None posted
Solicitation
  • Nov 30, 2024
    Combined Synopsis/Solicitation
    Open
  • Dec 20, 2024
    Combined Synopsis/Solicitation
    Open
  • Jan 14, 2025
    Combined Synopsis/Solicitation
    Open
Award
  • Jul 8, 2026 · this notice
    Award Notice
    SRI INTERNATIONAL Menlo Park CA 94025 USA · $49.9M
  • Jul 8, 2026
    Award Notice
    KYMANOX CORP · $49.9M
    Open
  • Jul 8, 2026
    Award Notice
    MURTY PHARMACEUTICALS, INC. · $49.9M
    Open
  • Jul 8, 2026
    Award Notice
    EMINENT SERVICES CORP · $49.9M
    Open

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Note the winner and the end of the period of performance for the recompete.
  • Follow the agency to see the next notice for this work.

What the notice says

A competitive multiple award, Indefinite Delivery/Indefinite Quantity (ID/IQ) type contract was awarded, with a ordering period (July 3, 2026 through July 31, 2031). It is anticipated that Task Orders issued against these contracts will most likely be cost-reimbursement, term/completion type Task Orders. Upon analysis of the type of work and all associated costs involved, fixed-price type task orders are usually not feasible due to the absence of precise specifications and difficulties in estimating costs with accuracy. Based upon the uncertainties involved, the Government would assume undue r… (show all)

isk in attempting to fit relatively dynamic (science responsive and result-drive) requirement into a fixed-price environment. In these instances, fixed-price task orders would be disadvantageous to the Government, since they do not provide the Government with the flexibility that is needed to reasonably and responsively shift with the evolving needs of this requirement. However, fixed price Task Order may be issued, where appropriate and feasible. The Contractor is eligible for Task Orders under Technical Area 1. The award notice is in relation to Solicitation # 75N95025R00005.

Who won similar work

26 award notices on SAM.gov in the last 24 months. Matched by: Same office (NATIONAL INSTITUTES OF HEALTH NIAID), same product/service code (PSC) AN12.

Single-winner award sizes (18): middle half $4.2M to $48.0M, median $24.8M; range $10K to $48.0M.

WinnerAwardsValueLast
SIA PARTNERS U.S., INC.2$48.0M + 1 sharedOct 7, 2026
PPD DEVELOPMENT LP1$48.0MOct 7, 2026
AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA1$48.0MOct 7, 2026
ADVANCED BIOSCIENCE LABORATORIES, INC.1$48.0MOct 7, 2026
BCG FEDERAL CORP.1$48.0MOct 7, 2026
FISHER BIOSERVICES INC · $TMO · $42.9B1$48.0MOct 7, 2026
EMINENT SERVICES CORP1$32.9MMar 30, 2026
DUKE UNIVERSITY Durham NC 27705 USA1$28.3MMar 31, 2025
Quality Biological, Inc1$25.4MApr 9, 2025
LA JOLLA INSTITUTE FOR IMMUNOLOGY La Jolla CA 92037 USA1$24.3MMar 16, 2026

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Investor context
  • $TMO reported $42.9B revenue in FY2025. The median single-winner award in these 18 past awards, $24.8M, is under 0.1% of that. 10-K

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 1 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (7 filings)
  • 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
  • $64K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 8 bills named on the past winners' lobbying filings
  • 0 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 1 of the past winners are listed companies
  • 0 insider buys and 7 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.